Analyst Rating Update on Intrexon Corporation (XON)

Intrexon Corporation (NYSE:XON) : Zacks Investment Research ranks Intrexon Corporation (NYSE:XON) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 7 research analysts is 1.86, which indicates as a Buy.

Intrexon Corporation (NYSE:XON) stock is expected to deviate a maximum of $12.68 from the average target price of $48.13 for the short term period. 8 Street Experts have initiated coverage on the stock with the most promising target being $65 and the most muted being $29.

For the current week, the company shares have a recommendation consensus of Buy. Also, JMP Securities initiates coverage on Intrexon Corporation (NYSE:XON). The shares have now been rated Market Outperform by the stock experts at the ratings house. The rating by the firm was issued on May 3, 2016.

Intrexon Corporation (NYSE:XON): On Tuesdays trading session , Opening price of the stock was $24.29 with an intraday high of $24.8. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $23.55. However, the stock managed to close at $23.82, a loss of 0.71% for the day. On the previous day, the stock had closed at $23.99. The total traded volume of the day was 2,092,458 shares.

In an insider trading activity, Kirk Randal J, CEO of Intrexon Corp, had purchased 124,475 shares on December 11, 2015. The total value of the transaction was $3,714,334. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.